News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cyto Pulse Sciences, Inc., the Karolinska Hospital/Institutet and SMI Receive Approval from the Swedish Medical Products Agency to Start a Clinical Trial Evaluating a CEA-based Vaccine in Patients with Colorectal Cancer.


11/4/2009 11:04:53 AM

GLEN BURNIE, Md.--(BUSINESS WIRE)--Cyto Pulse Sciences, a leading producer of electric field based, intradermal DNA Vaccine delivery systems, today announced approval by the Swedish regulatory authorities to begin a Phase I/II study of DNA vaccination in patients with colorectal cancer. The trial will investigate the safety of a DNA vaccine delivered by the Derma Vax™ intradermal electroporation system. The vaccine, which encodes Carcinoembryonic Antigen (CEA), was developed jointly by the Swedish Institute for Infectious Disease Control (SMI)/Karolinska Institutet (KI) and Cyto Pulse.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES